Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Emibetuzumab |
Synonyms | |
Therapy Description |
Emibetuzumab (LY2875358) is MET-targeted antibody, which inhibits binding of the MET ligand HGF and promotes internalization and downregulation of MET, resulting in decreased HGF-dependent and HGF-independent signaling and potentially leading to decreased growth of MET-expressing tumors (PMID: 27803065, PMID: 25231402). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Emibetuzumab | LY2875358 | MET Antibody 20 MET Inhibitor 53 | Emibetuzumab (LY2875358) is MET-targeted antibody, which inhibits binding of the MET ligand HGF and promotes internalization and downregulation of MET, resulting in decreased HGF-dependent and HGF-independent signaling and potentially leading to decreased growth of MET-expressing tumors (PMID: 27803065, PMID: 25231402, PMID: 31622732). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01287546 | Phase I | Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab | A Study of LY2875358 in Participants With Advanced Cancer | Completed | USA | 0 |
NCT01900652 | Phase II | Emibetuzumab + Erlotinib Emibetuzumab | A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants | Completed | USA | ITA | FRA | ESP | DEU | BEL | 4 |